<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Alternate Name</th>
        <th class="naaccr-summary-header naaccr-borders">Item#</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Column #</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders">Pathologic Stage (Prefix/Suffix) Descriptor (CoC)</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">920</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">CoC</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">956-956</td>
    </tr>
</table>

<br/><b>Description</b><br/>
Identified the AJCC pathologic stage (prefix/suffix) descriptor as recorded by the physician. AJCC stage descriptors identify special cases that need separate data analysis. The descriptors are adjuncts to and do not change the stage group.<br/>
<br/>
Pathologic and clinical stage data are given three separate areas in the NAACCR Data Exchange Record Layout. CoC defines a descriptor and "Staged By" item for each of these three areas.

<br/><br/><b>Rationale</b><br/>
CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.

<br/><br/><b>Codes</b><br/>
<table class="naaccr-codes-table">
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">0</td>
        <td class="naaccr-codes-cell">None</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">1</td>
        <td class="naaccr-codes-cell">E (Extranodal, lymphomas only)</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">2</td>
        <td class="naaccr-codes-cell">S (Spleen, lymphomas only)</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">3</td>
        <td class="naaccr-codes-cell">M (Multiple primary tumors in a single site)</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">4</td>
        <td class="naaccr-codes-cell">Y (Classification during or after initial multimodality therapy)-pathologic staging only</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">5</td>
        <td class="naaccr-codes-cell">E &amp; S (Extranodal and spleen, lymphomas only)</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">6</td>
        <td class="naaccr-codes-cell">M &amp; Y (Multiple primary tumors and initial multimodality therapy)</td>
    </tr>
    <tr>
        <td class="naaccr-codes-cell naaccr-codes-padding naaccr-codes-nowrap">9</td>
        <td class="naaccr-codes-cell">Unknown, not stated in patient record</td>
    </tr>
</table>
